Why the bone question is harder than the muscle question
A plausible mechanism, a measurable change, and no outcome data. This is what an open question looks like.
Trial design
Page 3 of 32 of this archive, newest first.
SURMOUNT-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Shenzhen: 23 posters, one theme
Reported from the sessions, and from the two hours afterwards.
SUSTAIN-6 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
STEP 1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Fat mass fell more than lean mass. That is the finding, and it is not the headline.
A substudy powered to describe a mean is not a substudy powered to detect a clinically meaningful individual change.
SURMOUNT-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
From the floor in Wuxi: 14 posters, one theme
Reported from the sessions, and from the two hours afterwards.
SURPASS-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Chengdu: 10 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
From the floor in Xi'an: 11 posters, one theme
Reported from the sessions, and from the two hours afterwards.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.